Spruce Capital Partners — 2015 Investments
1 investments dated 2015 · listed companies and verified rows first · show all
Evolve Biosystemsevolvebiosystems.comin𝕏Jul 2015
Evolve Biosystems develops probiotic strains of B. infantis, including EVC001 and a next-generation drug strain INF108, aimed at supporting the infant gut microbiome and preventing necrotizing enterocolitis (NEC) in premature infants.
BiotechHealthtechMedical DevicesDavis, US
J. Bruce German(Director)David Mills(Executive Officer)David J. Kyle(Executive Officer, Director)John Campbell(Executive Officer)James Campbell(Executive Officer)
BoardDaniel Janney(Director)
Co-investorsiSelect Fund
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.